Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to ...

Harvey Jones has spotted signs of life in the GSK share price. Which is a relief after its recent troubles, so can the FTSE ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Shai Biran; Investor Relations; Spero Therapeutics Inc. Esther Rajavelu; Interim President, Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Chief Business Officer; Spero ...

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analy ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...

Haleon was a joint venture between Pfizer and GSK before being listed in London as a separate company in 2022. GSK sold its remaining 4.2% holding in Haleon in May last year. Comments and questions to ...

Good evening and welcome to Dyadic International's Year-End 2024 Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, there will be a brief ...

GSK has teamed up with the University of Oxford on a programme that will try to identify the molecular changes in cells in precancerous stages that could form the basis of vaccines to prevent full ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...